Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney

M W Taal1, K Zandi-Nejad, B Weening

  • 1Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115-6110, USA. mtaal@rics.bwh.harvard.edu

Kidney International
|September 30, 2000
PubMed
Abstract

Insights

Macrophage infiltration drives chronic kidney injury after nephrectomy. ACE inhibitors and ARBs reduced this infiltration and protected against renal damage by targeting the renin-angiotensin system.

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Macrophage infiltration is implicated in chronic kidney injury.
  • Investigating gene expression related to macrophage recruitment in a rat remnant kidney model is crucial.

Purpose of the Study:

  • To examine the expression of genes involved in macrophage recruitment in the rat remnant kidney model.
  • To assess the effects of enalapril and candesartan on these gene expressions and renal injury.

Main Methods:

  • Utilized a rat remnant kidney model (5/6 nephrectomy).
  • Employed quantitative reverse transcription-polymerase chain reaction to measure mRNA levels of key genes (VCAM-1, ICAM-1, MCP-1, IL-1beta, TNF-alpha, TGF-beta1).
  • Administered enalapril or candesartan and evaluated systolic blood pressure, urinary protein excretion, and renal histology.

Main Results:

  • Vehicle-treated rats showed increased macrophage infiltration, MCP-1, and TGF-beta1, followed by ICAM-1, VCAM-1, IL-1beta, and TNF-alpha.
  • Both enalapril and candesartan normalized blood pressure and proteinuria.
  • Treatments significantly reduced renal injury, macrophage infiltration, and most cytokine expressions compared to vehicle control.

Conclusions:

  • Coordinated upregulation of molecules regulating macrophage recruitment is a key response to renal mass ablation.
  • This response is dependent on the renin-angiotensin system.
  • These molecular changes may contribute to glomerulosclerosis and tubulointerstitial fibrosis in chronic kidney disease.